惯性聚合 高效追踪和阅读你感兴趣的博客、新闻、科技资讯
阅读原文 在惯性聚合中打开

推荐订阅源

U
Unit 42
A
About on SuperTechFans
J
Java Code Geeks
H
Hackread – Cybersecurity News, Data Breaches, AI and More
Stack Overflow Blog
Stack Overflow Blog
Recent Announcements
Recent Announcements
GbyAI
GbyAI
F
Fortinet All Blogs
Blog — PlanetScale
Blog — PlanetScale
MongoDB | Blog
MongoDB | Blog
MyScale Blog
MyScale Blog
aimingoo的专栏
aimingoo的专栏
H
Help Net Security
月光博客
月光博客
博客园 - Franky
钛媒体:引领未来商业与生活新知
钛媒体:引领未来商业与生活新知
Apple Machine Learning Research
Apple Machine Learning Research
The Cloudflare Blog
WordPress大学
WordPress大学
S
SegmentFault 最新的问题
T
Tailwind CSS Blog
Jina AI
Jina AI
有赞技术团队
有赞技术团队
博客园_首页

All Articles on Seeking Alpha

All Eyes On Cencora, A Healthcare Supplier That Could See Lots More Upside Simply Good Foods Doesn't Look Like A Growth Stock Anymore Applied Digital: Post-Earnings Clarity Confirms An Accelerated Path To $1 Billion NOI Target IBIT: Why I Stepped To The Side (Technical Analysis) (Rating Downgrade) XES: Oil Service Stocks Turn Pricey; Why It's Time To Take Profits (Rating Downgrade) The Only Dividend Strategy I'd Trust In A 3.5% Fed Funds World Opera: AI-Driven Advertising Prospects - Upside Potential And Rich Dividend Yields RenaissanceRe: Preferred Stock Hasn't Been This Appealing In Years Q1 Earnings Kick Off With Major Banks' Results: Bank of America, Netflix In Focus Sezzle: Consolidation Completed, Re-Rating Ahead Bitmine Immersion Q2 Preview: Ethereum Thesis Facing Important Report Card I Am Sharing 2 Of My Retirement High-Yield Gems The Software Narrative Is Leaking Badly Again Thanks To Anthropic Mythos The Muni Market Looks Appealing In Q2 AVIV: Should Keep Rising If The Ceasefire Holds Foundayo Explained: Lilly's New Weight Loss Pill And The Amazon Effect Sabesp: A New Privatization As An Opportunity! EchoStar: Potential Bull Trap At Play - Take Gains Off The Table Teladoc Health: Improving Fundamentals Support A Turnaround Story March CPI Inflation: 5 Reasons To Stay Calm Two 12%+ Yielding BDC Bargains (One Is My Top Deep-Value Pick) TechnipFMC: We Prefer Saipem With More Room To Improve Tesla: From Bye-Bye To Buy-Buy (Rating Upgrade) DMB: Vulnerable To High Interest Rates Western Midstream: A 9% Yield That Still Grows In A Downturn IQQQ: Tax-Efficient Income From The Nasdaq But Does Not Protect Against Declines Qualys Share Price Pulled Down By Potential Cybersecurity Disruptor S&P 500: A Dead Money Era May Be Here. How To Thrive In It Vistance Networks Looks Better Than Before With Powerful Earnings Growth Commerce Bancshares: Valuation, Not Quality, Is The Problem
Ocular Therapeutix, Inc. (OCUL) Analyst/Investor Day Tran...
SA Transcripts · 2026-06-18 · via All Articles on Seeking Alpha

Ocular Therapeutix, Inc. (OCUL) Analyst/Investor Day June 17, 2026 2:00 PM EDT

Company Participants

Pravin Dugel - Executive Chairman, President & CEO
Nadia Waheed - Chief Medical Officer
Peter Kaiser - Chief Development Officer
Art Ciociola - Chief Regulatory & Quality Officer
David Robinson - Global Chief Commercial Officer
Jeffrey Heier, - Chief Scientific Officer

Conference Call Participants

Arshad Khanani - Sierra Eye Associates
Lejla Vajzovic
Darius M. Moshfeghi
Biren Amin - Piper Sandler & Co., Research Division
Tara Bancroft - TD Cowen, Research Division
Lisa Walter - RBC Capital Markets, Research Division
Serge Belanger - Needham & Company, LLC, Research Division
Lachlan Hanbury-Brown - William Blair & Company L.L.C., Research Division

Conversation

Unknown Executive

All right. Good afternoon, everyone. We're going to go ahead and get started here. Welcome to the Ocular Therapeutix 2026 Investor Day. So during today's presentation, certain statements we will be making constitute forward-looking statements under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Actual results may differ materially as a result of a variety of factors, including risks and uncertainties identified in the Risk Factors section of our annual report on Form 10-K and our other SEC filings. With that in mind, it is my pleasure to introduce Dr. Pravin Dugel, Ocular's Executive Chairman, President, and CEO.

Pravin Dugel
Executive Chairman, President & CEO

Good afternoon, and thanks for being here. This is a terrific day for us, and I really appreciate you spending the afternoon with us. You'll hear a lot of data today. You'll hear a lot about our strategy today, and you'll hear also why we're so incredibly excited to have you here.

The last time we were here in this very place was in September. And at that time, for those of you who are here, which I think is most of you, I said that I would like